Core Viewpoint - The U.S. FDA has approved the IND application for LBL-047, a novel drug developed by the company, indicating significant progress in its clinical development [1] Company Summary - LBL-047 is a bispecific fusion protein targeting BDCA2 and TACI, which has not been approved or entered clinical stages globally, highlighting its first-in-class potential [1]